Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review

被引：295

作者：

Stewart, Erin L. ^{[1
,2
]}

Tan, Samuel Zhixing ^{[1
,3
]}

Liu, Geoffrey ^{[1
,2
,4
]}

Tsao, Ming-Sound ^{[1
,2
,3
]}

机构：

[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada

[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada

[4] Univ Toronto, Dept Med, Toronto, ON, Canada

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2015年 / 4卷 / 01期

关键词：

Epidermal growth factor receptor (EGFR); molecular targeted therapy; drug resistance; antineoplastic;

D O I：

10.3978/j.issn.2218-6751.2014.11.06

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the leading cause of cancer related deaths in Canada with non-small cell lung cancer (NSCLC) being the predominant form of the disease. Tumor characterization can identify cancerdriving mutations as treatment targets. One of the most successful examples of cancer targeted therapy is inhibition of mutated epidermal growth factor receptor (EGFR), which occurs in similar to 10-30% of NSCLC patients. While this treatment has benefited many patients with activating EGFR mutations, almost all who initially benefited will eventually acquire resistance. Approximately 50% of cases of acquired resistance (AR) are due to a secondary T790M mutation in exon 20 of the EGFR gene; however, many of the remaining mechanisms of resistance are still unknown. Much work has been done to elucidate the remaining mechanisms of resistance. This review aims to highlight both the mechanisms of resistance that have already been identified in patients and potential novel mechanisms identified in preclinical models which have yet to be validated in the patient settings.

引用

页码：67 / 81

页数：15

共 141 条

[81] Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer [J].

Pao, William ;

Chmielecki, Juliann .

NATURE REVIEWS CANCER, 2010, 10 (11) :760-774

[82] Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens [J].

Querings, Silvia ;

Altmueller, Janine ;

Ansen, Sascha ;

Zander, Thomas ;

Seidel, Danila ;

Gabler, Franziska ;

Peifer, Martin ;

Markert, Eva ;

Stemshorn, Kathryn ;

Timmermann, Bernd ;

Saal, Beate ;

Klose, Stefan ;

Ernestus, Karen ;

Scheffler, Matthias ;

Engel-Riedel, Walburga ;

Stoelben, Erich ;

Brambilla, Elisabeth ;

Wolf, Juergen ;

Nuernberg, Peter ;

Thomas, Roman K. .

PLOS ONE, 2011, 6 (05)

[83]

Ramalingam SS, 2014, J CLIN ONCOL, P32

[84] Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer [J].

Ramalingam, Suresh S. ;

Blackhall, Fiona ;

Krzakowski, Maciej ;

Barrios, Carlos H. ;

Park, Keunchil ;

Bover, Isabel ;

Heo, Dae Seog ;

Rosell, Rafael ;

Talbot, Denis C. ;

Frank, Richard ;

Letrent, Stephen P. ;

Ruiz-Garcia, Ana ;

Taylor, Ian ;

Liang, Jane Q. ;

Campbell, Alicyn K. ;

O'Connell, Joseph ;

Boyer, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) :3337-3344

[85] Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung Cancer [J].

Ramalingam, Suresh S. ;

Spigel, David R. ;

Chen, David ;

Steins, Martin B. ;

Engelman, Jeffrey A. ;

Schneider, Claus-Peter ;

Novello, Silvia ;

Eberhardt, Wilfried E. E. ;

Crino, Lucio ;

Habben, Kai ;

Liu, Lian ;

Jaenne, Pasi A. ;

Brownstein, Carrie M. ;

Reck, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) :4574-4580

[86] Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer [J].

Regales, Lucia ;

Gong, Yixuan ;

Shen, Ronglai ;

de Stanchina, Elisa ;

Vivanco, Igor ;

Goel, Aviva ;

Koutcher, Jason A. ;

Spassova, Maria ;

Ouerfelli, Ouathek ;

Mellinghoff, Ingo K. ;

Zakowski, Maureen F. ;

Politi, Katerina A. ;

Pao, William .

JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (10) :3000-3010

[87] Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line [J].

Rho, Jin Kyung ;

Choi, Yun Jung ;

Lee, Jin Kyung ;

Ryoo, Baek-Yeol ;

Na, Im Il ;

Yang, Sung Hyun ;

Kim, Cheol Hyeon ;

Lee, Jae Cheol .

LUNG CANCER, 2009, 63 (02) :219-226

[88]

Rosell R, 2012, J CLIN ONCOL S, V30

[89] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[90] Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations [J].

Rosell, Rafael ;

Angel Molina, Miguel ;

Costa, Carlota ;

Simonetti, Sara ;

Gimenez-Capitan, Ana ;

Bertran-Alamillo, Jordi ;

Mayo, Clara ;

Moran, Teresa ;

Mendez, Pedro ;

Cardenal, Felipe ;

Isla, Dolores ;

Provencio, Mariano ;

Cobo, Manuel ;

Insa, Amelia ;

Garcia-Campelo, Rosario ;

Reguart, Noemi ;

Majem, Margarita ;

Viteri, Santiago ;

Carcereny, Enric ;

Porta, Ruth ;

Massuti, Bartomeu ;

Queralt, Cristina ;

de Aguirre, Itziar ;

Miguel Sanchez, Jose ;

Sanchez-Ronco, Maria ;

Luis Mate, Jose ;

Ariza, Aurelio ;

Benlloch, Susana ;

Javier Sanchez, Jose ;

Bivona, Trever G. ;

Sawyers, Charles L. ;

Taron, Miquel .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :1160-1168

← 4 5 6 7 8 9 10 11 12 13 →